title: Pomalidomide for multiple myeloma.
abstract: Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of 'novel agents': proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This drug profile focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.
authors.affiliation: Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M. Polonovski, 59037 Lille, France.
authors.forename: Guillemette
authors.initials: G
authors.lastname: Fouquet
authors.forename: Claire
authors.initials: C
authors.lastname: Bories
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Guidez
authors.forename: Loïc
authors.initials: L
authors.lastname: Renaud
authors.forename: Charles
authors.initials: C
authors.lastname: Herbaux
authors.forename: Sahir
authors.initials: S
authors.lastname: Javed
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007155:Immunologic Factors; D009842:Oligopeptides; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; C524865:carfilzomib; C467566:pomalidomide; D000077269:Lenalidomide
keywords: IMiDs; immunomodulation; multiple myeloma; pomalidomide; relapse refractory